Smith & Nephew plc (NYSE:SNN) Shares Sold by HighTower Advisors LLC

HighTower Advisors LLC trimmed its holdings in Smith & Nephew plc (NYSE:SNN) by 19.9% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 19,626 shares of the medical equipment provider’s stock after selling 4,864 shares during the period. HighTower Advisors LLC’s holdings in Smith & Nephew were worth $604,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. International Assets Investment Management LLC purchased a new stake in Smith & Nephew during the 3rd quarter valued at approximately $792,000. Sanctuary Advisors LLC purchased a new position in shares of Smith & Nephew in the 2nd quarter valued at approximately $627,000. Bank of Montreal Can increased its holdings in shares of Smith & Nephew by 355.8% in the second quarter. Bank of Montreal Can now owns 1,235,916 shares of the medical equipment provider’s stock valued at $31,059,000 after purchasing an additional 964,762 shares during the period. Brandes Investment Partners LP raised its stake in shares of Smith & Nephew by 20.5% during the second quarter. Brandes Investment Partners LP now owns 1,373,051 shares of the medical equipment provider’s stock worth $34,002,000 after purchasing an additional 233,293 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Smith & Nephew by 58.2% during the second quarter. Dimensional Fund Advisors LP now owns 524,602 shares of the medical equipment provider’s stock worth $12,995,000 after purchasing an additional 193,046 shares during the period. Institutional investors and hedge funds own 25.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on SNN. Berenberg Bank cut shares of Smith & Nephew from a “buy” rating to a “hold” rating in a research note on Wednesday, November 6th. Deutsche Bank Aktiengesellschaft lowered shares of Smith & Nephew from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Finally, StockNews.com downgraded shares of Smith & Nephew from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 12th.

Smith & Nephew Stock Down 0.4 %

Smith & Nephew stock opened at $24.79 on Friday. The stock’s 50 day moving average price is $26.29 and its 200 day moving average price is $27.88. Smith & Nephew plc has a 1-year low of $23.65 and a 1-year high of $31.72. The company has a market cap of $10.84 billion, a PE ratio of 12.65, a price-to-earnings-growth ratio of 1.41 and a beta of 0.84. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.51 and a quick ratio of 1.11.

Smith & Nephew Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.